ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Comparison of Pharmacokinetics and Pharmacogenomics of Once-Daily Extended-Release MeltDose® Tacrolimus Tablets (Envarsus® XR) Vs. Twice-Daily Tacrolimus Capsules in Stable African American Kidney Transplant Patients: A Randomized Cross-Over Study

J. Trofe-Clark,1,2 D. Brennan,3 P. West-Thielke,4 M. Milone,5 M. Lim,2 R. Bloom.2

1Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia
2Renal Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia
3Renal Division, Washington University, St. Louis
4University of Illinois at Chicago, Chicago
5Penn Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Meeting: 2015 American Transplant Congress

Abstract number: B76

Keywords: Immunosuppression

Session Information

Session Name: Poster Session B: Clinical Science: Kidney Immunosuppression: Novel Agents

Session Type: Poster Session

Date: Sunday, May 3, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

The CYP3A5 genotype is the most significant genetic factor impacting tacrolimus (tac) metabolism; expresser's of this genotype require higher tac doses to achieve therapeutic tac blood concentrations compare to non-expressers. Expression of CYP3A5*1 is most commonly found among African Americans (AA). Envarsus® XR is a novel, extended-release, once-daily, MeltDose® formulation of tac which has shown improved pharmacokinetics (PK), noninferior efficacy and similar safety in kidney transplant recipients (KTR) at a lower total daily dose vs. twice-daily tac capsules (Prograf®). A pooled analysis of data from phase 3 trials in de novo and stable black KTR showed a significantly decreased risk for treatment failure for Envarsus® XR vs. Prograf®. The primary objective of the present randomized, open-label, two sequence, three period crossover study is to compare the steady state PK of Envarsus® XR once-daily to tac capsules twice-daily (tac bid) in stable AA KTR. Secondary objectives include analyzing the impact of polymorphic genotype expression. Safety and efficacy, quality of life, and medication adherence, will also be compared between Envarsus® XR and tac bid. Planned enrollment is 72 stable AA KTR randomly assigned (1:1) to one of two sequences; Sequence 1: (n=36) 18 patients requiring <0.15mg/kg/day and 18 patients requiring ≥0.15mg/kg/day. Patients will continue on tac bid on days 1-7 then switch to Envarsus® XR (at 15% lower dose); Sequence 2: (n=36) 18 patients requiring <0.15mg/kg/day and 18 patients requiring ≥0.15mg/kg/day. Patients will receive Envarsus® XR on days 1-7 then switch back to tac bid. Patients who complete the PK treatment period may participate in an extension study where they will continue on the assigned treatment for up to 6 months. To date 30 subjects have been enrolled. Results will be available mid 2015.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Trofe-Clark J, Brennan D, West-Thielke P, Milone M, Lim M, Bloom R. Comparison of Pharmacokinetics and Pharmacogenomics of Once-Daily Extended-Release MeltDose® Tacrolimus Tablets (Envarsus® XR) Vs. Twice-Daily Tacrolimus Capsules in Stable African American Kidney Transplant Patients: A Randomized Cross-Over Study [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-pharmacokinetics-and-pharmacogenomics-of-once-daily-extended-release-meltdose-tacrolimus-tablets-envarsus-xr-vs-twice-daily-tacrolimus-capsules-in-stable-african-american-ki/. Accessed June 7, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences